ChanRx, a Cleveland biopharmaceutical company, closed a Series A round led by Austin-based
Santé Ventures. Funds will be used for a Phase IIb clinical study of the company's intravenous formulation of vanoxerine, an anti-arrhythmia drug.
Click here for press release.